Trial Profile

A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 16 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Intepirdine (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Registrational
Acronyms MINDSET Extension
Sponsors Sio Gene Therapies [CEASED]

Most Recent Events

30 Jun 2018 Trail has been discuntinued in Spain according to European Clinical Trials Database record.
16 Mar 2018 Status changed from active, no longer recruiting to discontinued as Intepirdine did not meet its primary efficacy endpoints in lead-in study RVT-101-3001.
13 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Mar 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com